Related Links Educational Materials About Clinical Trials Clinical Trials: Questions and Answers Questions to Ask Your Doctor Drug Information from MedlinePlus

Alternate Title
Basic Trial Information
Trial Description
     Purpose
     Eligibility
     Treatment/Intervention
Trial Contact Information
Registry Information

Alternate Title

Phase II Study of Sunitinib Malate in Patients With Recurrent or Metastatic Endometrial Cancer

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
Phase II	Treatment	Active	18 and over	NCI	PMH-PHL-062 7713, PHL-062, NCT00478426

Trial Description

Purpose:

Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

This phase II trial is studying how well sunitinib works in treating patients with recurrent or metastatic endometrial cancer.

Eligibility:

Eligibility criteria include the following:

• At least 18 years old
• Measurable disease
• No brain metastases
• More than 4 weeks since chemotherapy or radiation therapy
• At least 4 weeks since surgery
• No previous bevacizumab, sorafenib, pazopanib, AZD2171, vatalanib, or VEGF Trap
• For more information about the eligibility criteria for this trial, refer to the Health Professional version.

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Treatment/Intervention:

Patients will receive sunitinib by mouth once a day for 4 weeks. Treatment may repeat every 6 weeks for as long as benefit is shown.

After finishing treatment, patients will be evaluated at 4 weeks.

Important:

For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

Princess Margaret Hospital

Amit Oza, MD, Protocol chair		Ph: 416-946-2818

U.S.A.
California
	Duarte
	City of Hope Comprehensive Cancer Center
		Clinical Trials Office - City of Hope Comprehensive Cancer Center	Ph:  800-826-4673
			Email: becomingapatient@coh.org
Illinois
	Chicago
	University of Chicago Cancer Research Center
		Clinical Trials Office - University of Chicago Cancer Research Center	Ph:  773-834-7424
Canada
Alberta
	Edmonton
	Cross Cancer Institute at University of Alberta
		Helen Steed, MD	Ph:  780-432-8560 ext. 1
British Columbia
	Vancouver
	British Columbia Cancer Agency - Vancouver Cancer Centre
		Paul Hoskins, MD	Ph:  604-877-6000 ext. 2365 800-663-3333
Ontario
	Hamilton
	Margaret and Charles Juravinski Cancer Centre
		Hal Hirte, MD, FRCP(C)	Ph:  905-387-9495 ext. 6460
			Email: Hal.Hirte@jcc.hhsc.ca
	Kingston
	Cancer Centre of Southeastern Ontario at Kingston General Hospital
		James Biagi, MD	Ph:  613-544-2630 ext. 4502
	Ottawa
	Ottawa Hospital Regional Cancer Centre - General Campus
		Michael Fung Kee Fung, MD	Ph:  613-737-8560 888-627-5346
	Toronto
	Edmond Odette Cancer Centre at Sunnybrook
		Allan Covens, MD	Ph:  416-480-4026
			Email: al.covens@sunnybrook.ca
	Princess Margaret Hospital
		Amit Oza, MD	Ph:  416-946-2818
Quebec
	Montreal
	McGill Cancer Centre at McGill University
		Susie Lau, MD	Ph:  514-398-1444

Registry Information
Official Title		A Phase II Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma
Trial Start Date		2007-04-30
Trial Completion Date		2008-07-23 (estimated)
Registered in ClinicalTrials.gov		NCT00478426
Date Submitted to PDQ		2007-04-25
Information Last Verified		2007-12-21
NCI Grant/Contract Number		CM62203